Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IN3 Meeting In Brief

This article was originally published in The Gray Sheet

Executive Summary

CoaguSense: The Fremont, Calif., company hopes to win 510(k) approval for home use of its Immedia Meter to diagnose clot formation in January, CEO Douglas Patterson told investors Oct. 20 at the Investment in Innovation (IN3) Medical Device Summit in San Francisco (meeting was held Oct. 19-21 and organized by Elsevier Business Intelligence, publisher of "The Gray Sheet"). The prothrombin time/INR (international normalized ratio) assay is already available for use in providers' offices to help manage dosing for a patient on the blood thinner warfarin. Abbott bought the distribution rights for the home-based test version and plans to launch the assay by next March, pending FDA go-ahead. Medicare expanded national coverage of home-based PT/INR testing to patients taking warfarin for chronic atrial fibrillation or venous thromboembolism, and it was already covered for mechanical heart valve patients (1"The Gray Sheet" March 24, 2008). Immedia Meterrelies upon a finger-prick blood test and test strip inserted into a low-cost analyzer

You may also be interested in...



Home anti-coagulation monitoring

Medicare coverage is expanded for home blood testing of prothrombin time to include beneficiaries who are using the blood thinner warfarin for chronic atrial fibrillation or venous thromboembolism in a March 19 final coverage determination. Home International Normalized Ratio (INR) prothrombin time monitoring is already covered for patients with mechanical heart valves. The new policy should be a boon for three device firms that market INR assays for home use - Thoratec/International Technidyne (ProTime Microcoagulation System), Inverness/HemoSense (INRatio) and Roche Diagnostics (CaguChek XS and Coaguchek PST) ("1The Gray Sheet" Jan. 7, 2008, p. 16)

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.

Topics

UsernamePublicRestriction

Register

MT028141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel